Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia
Leukemia, 07/11/2012
Merkel O et al. – The results identify the clinically approved compound actinomycin D as a potentially valuable treatment option for Chronic lymphocytic leukemia (CLL) high–risk patients.



